Valneva SE announced on September 3, 2025, positive immunogenicity and safety data from the ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. The results demonstrated a strong anamnestic immune response and a favorable safety profile following a third booster dose, consistent with previous annual booster doses.
The latest data, measured one month after vaccination at month 42, showed a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5-11 years), adolescent (12-17 years), and adult (18-65 years) participants. Sero-conversion rates reached 100% for all outer surface protein A (OspA) serotypes in all age groups.
These results further reinforce the potential benefits of booster doses and VLA15's compatibility with a yearly vaccination schedule prior to each Lyme season. With no approved human vaccines for Lyme disease, and two Phase 3 trials nearing completion, these data move Valneva closer to making this vaccine available to communities in Lyme-endemic areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.